The month of October brought a flurry of events to ApeX Pharmaceuticals, a company co-founded by the IU School of Medicine’s Mark R. Kelley to develop novel compounds for cancer treatment.
On Oct. 10, the company announced the appointment of Steve Carchedi as president and CEO. Formerly CEO of Cornerstone Pharmaceuticals, a biotech firm that targets cancer metabolism, Carchedi has more than 30 years of industry experience in building biotech companies and also will serve on Apex’s board of directors. Former CEO David Broecker will continue to serve on the board as well.
On Oct. 23, the company changed its name to Apexian Pharmaceuticals and launched a new corporate website and Twitter handle @apexianpharma to reflect its progress in advancing some of its targeted drug candidates.
Recently, the company — which is backed in part by the Innovate Indiana Fund — was also accepted by the U.S. Food and Drug Administration for an Investigational New Drug Application to evaluate the tolerability and anti-tumor effects of APX3330, a small molecule in development to treat late stage cancer.